Archives of Clinical Infectious Diseases

Published by: Kowsar

Furazolidone-Based Quadruple Therapy for Eradication of Helicobacter pylori Infection in Peptic Ulcer Disease

Rahim Raoufi Jahromi 1 , Jamal Mirzaei 2 , Jalil Rajabi 2 , * , Seyed Javad Hoseini Shokouh 2 and Taraneh Liaghat 1
Authors Information
1 Department of Infectious Diseases, Jahrom University of Medical Sciences, Jahrom, IR Iran
2 Infectious Disease Research Center, Department of Infectious Diseases, Aja University of Medical Sciences, Tehran, IR Iran
Article information
  • Archives of Clinical Infectious Diseases: June 30, 2014, 9 (3); e18549
  • Published Online: June 25, 2014
  • Article Type: Research Article
  • Received: April 14, 2014
  • Accepted: May 30, 2014
  • DOI: 10.5812/archcid.18549

To Cite: Raoufi Jahromi R, Mirzaei J, Rajabi J, Hoseini Shokouh S J, Liaghat T. Furazolidone-Based Quadruple Therapy for Eradication of Helicobacter pylori Infection in Peptic Ulcer Disease, Arch Clin Infect Dis. 2014 ; 9(3):e18549. doi: 10.5812/archcid.18549.

Abstract
Copyright © 2014, Infectious Diseases and Tropical Medicine Research Center. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Objectives
3. Materials and Methods
4. Results
5. Discussion
Footnote
References
  • 1. Cheng H, Hu FL, Li J. [Influence of resistance of Helicobacter pylori to antibiotics on the Helicobacter pylori eradication regimens]. Zhonghua Yi Xue Za Zhi. 2006; 86(38): 2679-82[PubMed]
  • 2. Marshall BJ. The 1995 Albert Lasker Medical Research Award. Helicobacter pylori. The etiologic agent for peptic ulcer. JAMA. 1995; 274(13): 1064-6[PubMed]
  • 3. Ford AC, Delaney BC, Forman D, Moayyedi P. Eradication therapy in Helicobacter pylori positive peptic ulcer disease: systematic review and economic analysis. Am J Gastroenterol. 2004; 99(9): 1833-55[DOI][PubMed]
  • 4. Ables AZ, Simon I, Melton ER. Update on Helicobacter pylori treatment. Am Fam Physician. 2007; 75(3): 351-8[PubMed]
  • 5. Howden C. Helicobacter pylori-related peptic ulcer disease causation, diagnosis, treatment and complications. 2002; : 79-101
  • 6. Massarrat S, Saberi-Firoozi M, Soleimani A, Himmelmann GW, Hitzges M, Keshavarz H. Peptic ulcer disease, irritable bowel syndrome and constipation in two populations in Iran. Eur J Gastroenterol Hepatol. 1995; 7(5): 427-33[PubMed]
  • 7. Fuccio L, Zagari RM, Eusebi LH, Laterza L, Cennamo V, Ceroni L, et al. Meta-analysis: can Helicobacter pylori eradication treatment reduce the risk for gastric cancer? Ann Intern Med. 2009; 151(2): 121-8[PubMed]
  • 8. Zullo A, Ierardi E, Hassan C, De Francesco V. Furazolidone-based therapies for Helicobacter pylori infection: a pooled-data analysis. Saudi J Gastroenterol. 2012; 18(1): 11-7[DOI][PubMed]
  • 9. Siavoshi F, Pourkhajeh AH, Merat S. Susceptibility of various strains of Helicobacter pylorito selected agents. Arch Iranian Med. 2000; 3: 60-3
  • 10. World Gastroenterology Organisation Global Guideline: Helicobacter pylori in developing countries. J Clin Gastroenterol. 2011; 45(5): 383-8[DOI][PubMed]
  • 11. Coelho LG, Leon-Barua R, Quigley EM. Latin-American Consensus Conference on Helicobacter pylori infection. Latin-American National Gastroenterological Societies affiliated with the Inter-American Association of Gastroenterology (AIGE). Am J Gastroenterol. 2000; 95(10): 2688-91[DOI][PubMed]
  • 12. Treiber G, Ammon S, Malfertheiner P, Klotz U. Impact of furazolidone-based quadruple therapy for eradication of Helicobacter pylori after previous treatment failures. Helicobacter. 2002; 7(4): 225-31[PubMed]
  • 13. Roghani HS, Massarrat S, Shirekhoda M, Butorab Z. Effect of different doses of furazolidone with amoxicillin and omeprazole on eradication of Helicobacter pylori. J Gastroenterol Hepatol. 2003; 18(7): 778-82[PubMed]
  • 14. Malekzadeh R, Merat S, Derakhshan MH, Siavoshi F, Yazdanbod A, Mikaeli J, et al. Low Helicobacter pylori eradication rates with 4- and 7-day regimens in an Iranian population. J Gastroenterol Hepatol. 2003; 18(1): 13-7[PubMed]
  • 15. Ahmed HH, El-Aziem SH, Abdel-Wahhab MA. Potential role of cysteine and methionine in the protection against hormonal imbalance and mutagenicity induced by furazolidone in female rats. Toxicology. 2008; 243(1-2): 31-42[DOI][PubMed]
  • 16. Ali BH. Pharmacological, therapeutic and toxicological properties of furazolidone: some recent research. Vet Res Commun. 1999; 23(6): 343-60[PubMed]
  • 17. Jin X, Tang S, Chen Q, Zou J, Zhang T, Liu F, et al. Furazolidone induced oxidative DNA damage via up-regulating ROS that caused cell cycle arrest in human hepatoma G2 cells. Toxicol Lett. 2011; 201(3): 205-12[DOI][PubMed]
  • 18. De Francesco V, Ierardi E, Hassan C, Zullo A. Furazolidone therapy for Helicobacter pylori: is it effective and safe? World J Gastroenterol. 2009; 15(15): 1914-5[PubMed]
  • 19. De Francesco V, Ierardi E, Hassan C, Zullo A. Is furazolidone therapy for Helicobacter pylori effective and safe? Dig Dis Sci. 2009; 54(10): 2298-9[DOI][PubMed]
  • 20. Ma HJ, Wang JL. Quadruple therapy for eradication of Helicobacter pylori. World J Gastroenterol. 2013; 19(6): 931-5[DOI][PubMed]
  • 21. Snyder J. Multiple forms of exploitation in international research: the need for multiple standards of fairness. Am J Bioeth. 2010; 10(6): 40-1[DOI][PubMed]
  • 22. Gisbert JP, Pajares R, Pajares JM. Evolution of Helicobacter pylori therapy from a meta-analytical perspective. Helicobacter. 2007; 12 Suppl 2: 50-8[DOI][PubMed]
  • 23. Miura M, Satoh S, Tada H, Habuchi T, Suzuki T. Stereoselective metabolism of rabeprazole-thioether to rabeprazole by human liver microsomes. Eur J Clin Pharmacol. 2006; 62(2): 113-7[DOI][PubMed]
  • 24. Megraud F. H pylori antibiotic resistance: prevalence, importance, and advances in testing. Gut. 2004; 53(9): 1374-84[DOI][PubMed]
  • 25. Branca G, Spanu T, Cammarota G, Schito AM, Gasbarrini A, Gasbarrini GB, et al. High levels of dual resistance to clarithromycin and metronidazole and in vitro activity of levofloxacin against Helicobacter pylori isolates from patients after failure of therapy. Int J Antimicrob Agents. 2004; 24(5): 433-8[DOI][PubMed]
  • 26. Malekzadeh R, Ansari R, Vahedi H, Siavoshi F, Alizadeh BZ, Eshraghian MR, et al. Furazolidone versus metronidazole in quadruple therapy for eradication of Helicobacter pylori in duodenal ulcer disease. Aliment Pharmacol Ther. 2000; 14(3): 299-303[PubMed]
  • 27. Forta LC, da CMP, Luz CR. Helicobacter pylorieradication using tetracycline and furazolidone versus amoxicillin and azithromycin lansoprazole-based triple therapy: an open randomized clinical trial. Arq Gastroent J. 2005; 42: 111-5
  • 28. Lu H, Zhang DZ, Hu PJ, Li ZS, Lu XH, Fang XC, et al. One-week regimens containing ranitidine bismuth citrate, furazolidone and either amoxicillin or tetracycline effectively eradicate Helicobacter pylori: a multicentre, randomized, double-blind study. Aliment Pharmacol Ther. 2001; 15(12): 1975-9[PubMed]
  • 29. Fakheri H, Merat S, Hosseini V, Malekzadeh R. Low-dose furazolidone in triple and quadruple regimens for Helicobacter pylori eradication. Aliment Pharmacol Ther. 2004; 19(1): 89-93[PubMed]
  • 30. Ghadir MR, Shafaghi A, Iranikhah A, Pakdin A, Joukar F, Mansour-Ghanaei F. Furazolidone, amoxicillin and omeprazole with or without bismuth for eradication of Helicobacter pylori in peptic ulcer disease. Turk J Gastroenterol. 2011; 22(1): 1-5[PubMed]
  • 31. Saberi-Firoozi M, Nejabat M. Experiences with Helicobacter Pylori Treatment in Iran. IJMS. 2006; 31: 4-11
  • 32. Bahari A, Nezam SK, Karimi M. The comparison of two combination antibiotic [(OAB-T) VS (OAB-F)] regimen trophy in peptic ulcer and dyspepsia patients. Tabib shargh J. 2007; 9(4): 237-46
  • 33. Kashifard M, Taheri H, Barzkar M. Comparison the efficacy of furazolidone and Amoxicillin with Metronidazole and Amoxicillin in Quadruple therapy regimen with average dosage and duration against H.pylori. Babol Medic Sci J. 2006; 8(2): 24-31
  • 34. Talebi Bezminabadi A, Mohabati Mobarez A, Aiami AGH, Rafiee A, Taghwaii T. Evaluation on antibiotic resistance of helicobacter pylori isolated from patients admitted to tooba medical center, Sari. Mazandaran Medic Sci J. 2009; 19(70): 26-32
  • 35. Tirgar Fakheri H, Malekzadeh R, Hosseini VR. Eradication of helicobacter pylori using low dose furazolidone in triple and quadruple therapies versus metronidazole in triple therapy in deodenal ulcer patients. Mazandaran Medic Sci J. 2003; 13(40): 51-60
  • 36. Khatibian M, Ajvadi Y, Nasseri-Moghaddam S, Ebrahimi-Dariani N, Vahedi H, Zendehdel N, et al. Furazolidone-based, metronidazole-based, or a combination regimen for eradication of Helicobacter pylori in peptic ulcer disease. Arch Iran Med. 2007; 10(2): 161-7
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:

Author(s):

Article(s):

Create Citiation Alert
via Google Reader

Readers' Comments